Pulmonary Cell News Volume 11.20 | May 26 2022

    By
    Ishira
    -
    0
    25







    2022-05-26 | PULCN 11.20


    Pulmonary Cell News by STEMCELL Technologies
    Vol. 11.20 – 26 May, 2022
    TOP STORY

    Suppression of Nuclear GSK3 Signaling Promotes Serine/One-Carbon Metabolism and Confers Metabolic Vulnerability in Lung Cancer Cells

    Scientists uncovered a critical role of glycogen synthase kinase 3 (GSK3) in regulating the expression of serine/one-carbon metabolic enzymes.
    [Science Advances]

    Full Article
    Explore tools and resources for your return to the lab
    PUBLICATIONSRanked by the impact factor of the journal

    MERS-CoV Endoribonuclease and Accessory Proteins Jointly Evade Host Innate Immunity during Infection of Lung and Nasal Epithelial Cells

    Researchers investigated the antagonist effects of the conserved coronavirus endoribonuclease, in combination with NS4a or NS4b.
    [Proceedings of the National Academy of Sciences of the United States of America]

    Abstract

    Fgfr2b Signaling Is Essential for the Maintenance of the Alveolar Epithelial Type 2 Lineage during Lung Homeostasis in Mice

    The authors underscored the essential role played by fibroblast growth factor receptor 2b (Fgfr2b) signaling in the maintenance of the alveolar epithelial type 2 cells (AT2s) lineage in the adult lung during homeostasis and suggested that the IAAPs could represent a new population of AT2 progenitors.
    [Cellular and Molecular Life Sciences]

    Full Article

    Biological Interactions of Ferromagnetic Iron Oxide–Carbon Nanohybrids with Alveolar Epithelial Cells

    Hybrid nanoformulation showed no cytotoxic effects on a widely employed model of alveolar epithelial cells for a variety of concentrations and exposure times.
    [Biomaterials Science]

    AbstractGraphical Abstract

    The Involvement of Copper, Circular RNAs, and Inflammatory Cytokines in Chronic Respiratory Disease

    Researchers exposed the human bronchial epithelial cell line, 16HBE, to copper and assessed the functional role of a circRNA, circ_0008882, by RNA overexpression.
    [Chemosphere]

    AbstractGraphical Abstract

    Cytocompatibility of Pluronics F-127 on Adenocarcinomic Human Alveolar Basal Epithelial Cells (A549 Cells)

    Investigators explored the cytocompatibility of Pluronics F-127.The cells were exposed to varying concentrations of Pluronics F-127 in A549 cells for 24 hours.
    [Environmental Science and Pollution Research]

    AbstractGraphical Abstract

    Integrin α3/α6 and αV Are Implicated in ADAM15-Activated FAK and EGFR Signaling Pathway Individually and Promote Non-Small-Cell Lung Cancer Progression

    The authors fouond that disintegrin-metalloproteinase 15 (ADAM15) regulated the epidermal growth factor receptor/focal adhesion kinase (EGFR/FAK) signaling pathway by interactions with integrins.
    [Cell Death & Disease]

    Full Article

    Targeting Epidermal Growth Factor Receptor in Paclitaxel-Resistant Human Breast and Lung Cancer Cells with Upregulated Glucose-6-Phosphate Dehydrogenase

    EGFR signaling-mediated glucose-6-phosphate dehydrogenase (G6PD) expression plays a pivotal role in paclitaxel resistance, highlighting the potential of targeting EGFR to overcome paclitaxel resistance in triple-negative breast cancer and NSCLC cells overexpressing G6PD.
    [British Journal of Cancer]

    Abstract

    Iloprost Requires the Frizzled 9 Receptor to Prevent Lung Cancer

    Researchers established that iloprost required Frizzled9 in vivo for lung cancer chemoprevention.
    [iScience]

    AbstractFull ArticleGraphical Abstract

    ILDR1 Promotes Influenza a Virus Replication through Binding to PLSCR1

    Immunoglobulin-like domain-containing receptor 1 (ILDR1) was highly expressed in the lungs, and its expression level was increased after virus infection.
    [Scientific Reports]

    Full Article

    ADH1C Facilitates Cisplatin Resistance of Lung Adenocarcinoma Cells

    The authors indicated that the ADH1C/methionine adenosyltransferase axis possibly increased cisplatin resistance in lung adenocarcinoma cells.
    [DNA and Cell Biology]

    Abstract

    Silencing of lncRNA CRNDE Attenuates Non Small-Cell Lung Cancer Progression by Mediating the miR-455-3p/HDAC2 Axis

    CRNDE knockdown inhibited the viability, migration and invasion of NSCLC cells or epidermal growth factor receptor gene-mutant NSCLC cells.
    [Kaohsiung Journal of Medical Sciences]

    Full Article
    Virtual Conference Exhibition: Pluripotent Stem Cells
    REVIEWS

    Molecular Subtyping of Small Cell Lung Cancer

    The authors summarize the evolution of mutation-based molecular subtyping of SCLC, as well as the trends in molecular targeting and immunotherapeutic for SCLC.
    [Seminars in Cancer Biology]

    Abstract

    Cancer-Associated Fibroblasts in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Implications

    Scientists summarize the tumor-promoting role and molecular mechanisms of cancer-associated fibroblasts in NSCLC, including their origin, phenotypic changes and heterogeneity, and their functional roles in carcinogenesis.
    [International Journal of Cancer]

    Abstract

    Prognostic Value of Myosteatosis in Patients with Lung Cancer: A Systematic Review and Meta-Analysis

    Myosteatosis might serve as an independent indicator of unfavorable survival outcomes for overall survival and progression-free survival in lung cancer patients.
    [International Journal of Clinical Oncology]

    Abstract
    INDUSTRY AND POLICY NEWS

    Avalo Therapeutics Announces First Patient Dosed in the Phase II PEAK Trial of AVTX-002 for the Treatment of Non-Eosinophilic Asthma (NEA)

    Avalo Therapeutics, Inc. announced that the first patient has been dosed in the company’s Phase II PEAK trial evaluating AVTX-002 for the treatment of NEA.
    [Avalo Therapeutics, Inc.]

    Press Release

    Successful Completion of Phase I Study for Lead Asset EP395

    EpiEndo Pharmaceuticals, the clinical-stage biopharmaceutical company developing disease-modifying therapeutics for chronic respiratory disorders, has completed its Phase I First Time in Human study with EP395 in healthy subjects.
    [EpiEndo Pharmaceuticals (B3CNewswire, Inc.)]

    Press Release

    Therapeutic Solutions International Receives IND Number 28508 for Chronic Obstructive Pulmonary Disease Clinical Trial and Enters Binding Discussions with FDA for Initiation of Phase I/II Clinical Trial

    Therapeutic Solutions International announced today receiving Investigational New Drug application number #28508 from the FDA for its proposed clinical trial evaluating the JadiCellâ„¢ in treatment of COPD.
    [Therapeutic Solutions International (BusinessWire, Inc.)]

    Press Release
    FEATURED EVENT

    Cell UK

    November 7 – 8, 2022
    London, England, United Kingdom

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Position – Metabolic Vulnerabilities

    Memorial Sloan Kettering Cancer Center – New York, New York, United States

    Postdoctoral Positions – Lung Research

    Columbia University – New York, New York, United States

    Postdoctoral Research Scientist – Lung Infection

    Francis Crick Institute – London, United Kingdom

    Postdoctoral Position – Cancer Immunology

    Flanders Institute for Biotechnology – Brussels, Belgium

    Research Fellow – Respiratory Genomics

    Mayo Clinic – Scottsdale, Arizona, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Pulmonary Cell News Twitter